Cite
APA Citation
Werth, V., Hejazi, E., Pena, S., Haber, J., Okawa, J., Feng, R., Gabre, K., Concha, J., Cornwall, C., Dgetluck, N., Constantine, S., & White, B. (n.d.). fRI0470 A phase 2 study of safety and efficacy of lenabasum (JBT-101), a cannabinoid receptor type 2 agonist, in refractory skin-predominant dermatomyositis. Annals of the rheumatic diseases, 77, 763–764. http://access.bl.uk/ark:/81055/vdc_100144721123.0x00004c